Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Other Working Capital Changes (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Other Working Capital Changes for 7 consecutive years, with -$76000.0 as the latest value for Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 115.05% year-over-year to -$76000.0; the TTM value through Sep 2025 reached -$235000.0, down 339.8%, while the annual FY2024 figure was -$21000.0, 86.88% up from the prior year.
  • Other Working Capital Changes hit -$76000.0 in Q3 2025 for Cyclerion Therapeutics, down from $206000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.4 million in Q4 2021 and bottomed at -$1.4 million in Q3 2021.
  • Average Other Working Capital Changes over 5 years is -$12611.1, with a median of -$70500.0 recorded in 2022.
  • Year-over-year, Other Working Capital Changes soared 2268.25% in 2021 and then plummeted 5400.0% in 2023.
  • Cyclerion Therapeutics' Other Working Capital Changes stood at $1.4 million in 2021, then plummeted by 110.47% to -$143000.0 in 2022, then soared by 43.36% to -$81000.0 in 2023, then crashed by 146.91% to -$200000.0 in 2024, then soared by 62.0% to -$76000.0 in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$76000.0, $206000.0, and -$165000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.